Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group

C. G. Moertel, S. Frytak, R. G. Hahn, M. J. O'Connell, R. J. Reitemeier, J. Rubin, A. J. Schutt, L. H. Weiland, D. S. Childs, M. A. Holbrook, P. T. Lavin, E. Livstone, H. Spiro, A. Knowlton, M. Kalser, J. Barkin, H. Lessner, R. Mann‐Kaplan, K. Ramming, H. O. DouglasP. Thomas, H. Nave, J. Bateman, J. Lokich, J. Brooks, J. Chaffey, J. M. Corson, N. Zamcheck, Joel W. Novak

Research output: Contribution to journalArticlepeer-review

981 Scopus citations

Abstract

One‐hundred‐ninety‐four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high‐dose (6000 rads) radiation therapy alone, to moderate‐dose (4000 rads) radiation + 5‐fluorouracil (5‐FU), and to high‐dose radiation plus 5‐FU. Median survival with radiation alone was only 51/2 months from date of diagnosis. Both 5‐FU‐containing treatment regimens produced a highly significant survival improvement when compared with radiation alone. Forty percent of patients treated with the combined regimens were still living at one year compared with 10% of patients treated with radiation only. Survival differences between 4000 rads plus 5‐FU and 6000 rads plus 5‐FU were not significant with an overall median survival of ten months. Significant prognostic variables, in addition to treatment, were pretreatment performance status and pretreatment CEA level.

Original languageEnglish
Pages (from-to)1705-1710
Number of pages6
JournalCancer
Volume48
Issue number8
DOIs
StatePublished - 15 Oct 1981
Externally publishedYes

Fingerprint

Dive into the research topics of 'Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group'. Together they form a unique fingerprint.

Cite this